Cellulimine
Food supplement declared in France, declaration No 2018-3-1314, decision dated 28 March 2018
Cellulimine is a food supplement declared in France. Status: declared in France, may be marketed. 2 rules of use apply to its ingredients (limits and warnings).
- Brand
- not provided
- Food business operator placing the product on the market
- New Stefal Holding
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Tablet
- Daily dose
- 3 comprimés
- Directions for use
- Prendre trois comprimés de préférence le matin accompagnés d’un grand verre d’eau.
- Not recommended (according to the manufacturer)
- Adolescents (under 18), Breastfeeding women, Taking away from meals, Children (under 12), Young children (aged 1 to 3), Pregnant women, Infants (under 1 year), Taking anticoagulants
- Objectives stated by the manufacturer (these are not authorised claims)
- Slimming / Fat burner, Slimming / Appetite control, Slimming / Flat stomach
Declaration 154066, procedure Article 16. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Paullinia cupana Kunth | Graine | Extrait sec aqueux | 300 mg |
| Prunus cerasus L. | Queue | Extrait sec aqueux | 300 mg |
| Aesculus hippocastanum L. | Ecorce | Extrait fluide hydroalcoolique | 270 mg |
| Camellia sinensis (L.) Kuntze | Feuille | Extrait sec aqueux | 150 mg |
| Rosa canina L. | Faux fruit | Extrait sec aqueux | 150 mg |
| Fucus vesiculosus L. | Thalle | Extrait sec aqueux | 66.69 mg |
Other active ingredients
| Name | Per day |
|---|---|
| Citroflavonoïdes | not declared |
Additives
E460, E341, E470b, E551
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Regulatory points
- Conditions légales
Contains tea (Camellia sinensis). Green tea extracts must provide less than 800 mg of epigallocatechin-3-gallate per daily portion, with mandatory warnings.
Source: Regulation (EC) No 1925/2006, latest consolidated version, annexe III, partie B (règlement (UE) 2022/2340).
- Conditions légales
Camellia sinensis (L.) Kuntze: Seules sont admises la poudre issue du broyage des feuilles et les préparations obtenues à partir des solvants suivants : l'eau, l'alcool à 25 % (v/v), ainsi que les solvants autorisés pour la décaféination ou la suppression des matières irritantes et amères. Les recommandations d'emploi ne doivent pas conduire à une ingestion quotidienne d'EGCG supérieure à 300 mg. L'étiquetage doit comporter des avertissements déconseillant leur prise en dehors des repas, ainsi que leur consommation par les enfants, les adolescents, les femmes enceintes ou allaitantes.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Aesculus hippocastanum L.
Read the warning, when it applies and the studies cited
Horse Chestnut - Aesculus Hippocastanum
Route of administration: Oral (Bradley 2006; ESCOP 2003)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Brinker 2010; Mills and Bone 2005).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
Known adverse reactions
When using this product you may experience headache, dizziness, gastric irritation, or itchiness (Bradley 2006; Mills and Bone 2005; ESCOP 2003).
Sources cited by Health Canada (3)
- Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (UK): British Herbal Medicine Association; 2006.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- Cellulimine PHYDERMA, declared in 2026 : different composition: 2 ingredient(s) added, 1 missing
- CELLULIMINE New Stefal Holding, declared in 2017, earlier declaration, replaced by the 2018 declaration : different composition: 2 ingredient(s) added, 0 missing
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.